Form 4: Gilead Sciences Boosts Stake in Xilio Therapeutics with Significant Warrant Acquisition

Gilead Sciences, Inc., a 10% owner and director of Xilio Therapeutics, Inc., has acquired over 13 million units of prefunded and multi-series warrants, signaling a substantial investment in the biotechnology firm.

Summary

• Gilead Sciences, Inc. reported the acquisition of various warrants in Xilio Therapeutics, Inc. (XLO) on June 5, 2025.
• The transaction involved the purchase of 13,335,000 Prefunded Warrants, 13,335,000 Series A Warrants, 13,335,000 Series B Warrants, and 13,335,000 Series C Warrants.
• Each Prefunded Warrant was acquired together with an accompanying Series A, Series B, and Series C Warrant at a combined offering price of $0.7499 per unit.
• The Prefunded Warrants have an exercise price of $0.0001 and no expiration date, becoming exercisable immediately upon issuance.
• Series A Warrants have an exercise price of $0.75 and are exercisable from the earlier of December 1, 2025, or when Xilio's common stock closes at $1.50 or more for five consecutive trading days, expiring by June 5, 2030, or upon exercise of corresponding Prefunded Warrants.
• Series B Warrants have an exercise price of $0.75 and are exercisable from November 1, 2025, expiring on December 2, 2025, with a potential reset of the exercise price and extension to December 31, 2025, if the stock price is below the exercise price.
• Series C Warrants have an exercise price of $0.75 and are exercisable from June 1, 2026, expiring on the earlier of December 2, 2026, or the expiration of corresponding unexercised Series B Warrants, also with a potential exercise price reset and extension to December 31, 2026.
• Following the transaction, Gilead beneficially owns 23,310,266 Prefunded Warrants and 13,335,000 of each Series A, B, and C Warrants.
• A beneficial ownership limitation of 19.99% of Xilio's outstanding common stock applies to warrant exercises, as per Section 13(d) of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The acquisition of a significant warrant stake by a major pharmaceutical company like Gilead Sciences in Xilio Therapeutics is generally viewed positively, indicating strategic interest and providing capital to Xilio. However, potential future dilution from warrant exercise introduces some caution.

Positives

• Gilead Sciences, a major pharmaceutical company, is increasing its equity exposure to Xilio Therapeutics, potentially signaling confidence in Xilio's future prospects and technology.
• The acquisition of warrants provides Xilio Therapeutics with capital, which can support its ongoing operations and development programs.
• The Prefunded Warrants have a nominal exercise price ($0.0001) and no expiration date, offering long-term flexibility for Gilead to convert them into common stock.

Negatives

• The exercise of these warrants, particularly the large volume of 13,335,000 for each series, could lead to significant dilution for existing Xilio Therapeutics shareholders if converted into common stock.
• The complex terms and conditions for the exercisability and expiration of Series A, B, and C Warrants introduce uncertainty regarding their future conversion and potential impact.

Risks

• Potential future dilution of Xilio Therapeutics' common stock if Gilead Sciences exercises its warrants.
• Market price volatility of Xilio's common stock could affect the exercisability and value of the Series A, B, and C Warrants, especially given the reset clauses tied to stock price performance.
• The 19.99% beneficial ownership limitation may restrict Gilead's ability to fully exercise all warrants at once, potentially delaying full capital infusion from warrant exercise or limiting Gilead's immediate control.

Future Outlook

Gilead Sciences now holds a significant number of warrants in Xilio Therapeutics, providing it with the option to increase its common stock ownership in the future. The exercise of these warrants is contingent on various factors, including specific dates and Xilio's stock price performance, which could lead to substantial capital infusion for Xilio and increased ownership for Gilead.

Industry Context

This transaction highlights continued strategic investment by larger pharmaceutical companies like Gilead Sciences into smaller biotechnology firms such as Xilio Therapeutics. Such investments often aim to gain exposure to innovative pipelines or technologies, potentially leading to future collaborations, partnerships, or even acquisitions. The use of warrants is a common financing mechanism in the biotech sector, allowing companies to raise capital while providing investors with upside potential tied to future stock performance.

Comparison to Industry Standards

• The use of a multi-series warrant structure with varying exercise prices, dates, and reset clauses is a common financing tool in the biotechnology industry, particularly for companies seeking to align investor incentives with specific development milestones or stock price targets.
• The 19.99% beneficial ownership limitation is a standard provision often included in private placement transactions to avoid triggering certain regulatory requirements (e.g., 'poison pill' defenses or certain tender offer rules) that apply at higher ownership thresholds.
• While specific comparable companies or projects are not detailed, this type of strategic investment by a major pharmaceutical player like Gilead into a clinical-stage biotech like Xilio is a recognized pattern for pipeline expansion and risk diversification within the broader pharmaceutical and biotechnology landscape.

Related Party Transactions

• Gilead Sciences, Inc. is identified as both a Director and a 10% Owner of Xilio Therapeutics, Inc., making this warrant acquisition a related-party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised, but also a signal of confidence and capital infusion for the company.
• Company (Xilio Therapeutics): Receives immediate capital from the warrant issuance and potential future capital upon warrant exercise, supporting its operations and strategic goals.

Next Steps

• Gilead Sciences may choose to exercise its Prefunded Warrants at any time, converting them into common stock.
• Gilead Sciences may exercise Series A, B, and C Warrants based on their respective exercisability conditions and expiration dates, potentially increasing its ownership stake in Xilio Therapeutics.
• Xilio Therapeutics will utilize the capital raised from this warrant issuance to fund its operations and development pipeline.

Key Dates

Keywords

Xilio Therapeutics, Gilead Sciences, Warrants, SEC Form 4, Equity Ownership, Insider Transaction, Biotechnology Investment, Pharmaceutical Investment, Capital Raise, Dilution